Yun Liu

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, 311202, Zhejiang, China
Author    Correspondence author
Journal of Vaccine Research, 2024, Vol. 14, No. 3   
Received: 21 Apr., 2024    Accepted: 25 May, 2024    Published: 06 Jun., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study focuses on exploring the regulatory mechanisms that enhance graft longevity through genetically modified pig organs. The discussion centers on genetic modifications designed to improve immune compatibility and graft survival. Key gene editing technologies, such as CRISPR/Cas9, have enabled precise modifications of the pig genome, reducing immunogenicity and improving physiological compatibility. Experimental studies have shown the effectiveness of these modifications in preventing organ rejection and enhancing organ function in non-human primates and preliminary human trials. This study also addresses ethical considerations, including animal welfare and long-term genetic stability, as well as the regulatory frameworks governing xenotransplantation. It emphasizes the importance of interdisciplinary research, the development of immune tolerance strategies, and the integration of bioengineering approaches. This study highlights the potential of genetically modified pig organs as a viable solution to the organ shortage crisis, paving the way for future clinical applications.

Xenotransplantation; Genetic Modification; Graft Longevity; Immune Compatibility; CRISPR/Cas9